Texas judge suspends FDA approval of major abortion pill

A federal judge in Texas ordered the Food and Drug Administration to suspend its approval of a pill involved in roughly half of abortions nationwide. The decision would likely reduce the availability of abortions in states where the procedure is legal if not for an additional ruling Friday night ordering the opposite.

On Friday, U.S. District Judge Matthew Kacsmaryk took the side of anti-abortion activists. He decided to halt the FDA’s decades-old’s endorsement of mifepristone, the first of two abortion-inducing medications used to end pregnancy within 10 days. The choice will not go into effect until the Biden administration has had a month to file an appeal with the U.S. Court of Appeals for the 5th Circuit.

A critical abortion pill could be removed from the market by a Texas judge.

A federal judge in Washington think issued a decision that instantly contradicted Kacsmaryk’s decision’s not long after it was made. The FDA was mandated by the Washington decision to maintain the drug’s availability’s.

According to the New York Times, the Supreme Court is likely to hear the case because of the conflicting verdicts.

Four medics and a number of anti-abortion health organizations, including the American Association of Pro-Life Obstetricians and Gynecologists and the Alliance for Hippocratic Medicine, had argued that the FDA overstepped its regulatory authority when it approved mifepristone in 2000.

The Supreme Court’s decision’s to overturn Roe v. Wade last June, which made it possible for red states to enact strict abortion restrictions, led to the lawsuit.

Former President Donald Trump appointed Kacsmaryk, who issued a 67-page decision, in which he claimed that the FDA had failed to assess the pill’s psychological’s or long-term health effects despite its safety and effectiveness.

Additionally, he criticized the lack of testing for” under – 18 girls undergoing reproductive progress” and implied that the organization had submitted to social pressure in order to approve the medication.

According to Kacsmaryk,” The Court does not loosely second-guess FDA’s decision-making’s.” However, in this instance, the FDA gave in to its reasonable security concerns despite breaking the law and based on clearly flawed logic and reviews that did not support its conclusions.

TO READ MORE FROM THE WASHINGTON EXAMINER, CLICK HERE.

The FDA has emphasized time and time again that the pregnancy drug is a secure and efficient substitute for medical miscarriages. Reversing mifepristone’s approval’s did” cause serious and irreparable damage to individuals across the country ,” the American Medical Association, American College of Obstetricians and Gynecologists, and some health organizations argued in a court filing.

Although abortion rights organizations have previously warned that removing mifepristone from the market might force abortion clinics to just perform surgical abortions, flooding many facilities is unknown.